Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-03-07
2006-03-07
Cook, Rebecca (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
07008961
ABSTRACT:
Carcinoma is treated in a patient by administration of Rhodamine-123 (Rh-123) orally or by intravenous injection of a treatment solution of Rh-123, ethyl alcohol, dextrose, and water in an amount sufficient to effect in vivo destruction of cancer cells. The treatment solution is made by mixing a stock solution of Rh-123 in a solution of 95% ethyl alcohol and 5% water (by volume) with a solution of 5% (by weight) dextrose in water. For prostate cancer, treatment is controlled by measuring the level of prostate specific antigen (PSA), or prostate specific acid phosphatase in the blood of the patient.
REFERENCES:
patent: 5189029 (1993-02-01), Boyer et al.
patent: 5260327 (1993-11-01), Kim et al.
patent: 5360803 (1994-11-01), Shishido et al.
patent: 5880141 (1999-03-01), Tang et al.
Arcadi, J. Surgical Oncology, 44:103-108, 1990.
Arcadi, Urology, 28(6), 501-503, Dec. 1986.
Bernal et al., Science (1983), 222(4620), 160-72 Abstract Only.
EMBASE AN 04120900, Montaguti et al, Arzneimittle-Forschung/Drug Research, 1994, 44/4 566-570, abstract.
EMBASE 94148842, Gupta et al, PDA J. Pharmac. Sci. Tech, 1994 48/2 86-91, abstract.
MEDLINE AN 93172422, Kaplan et al, J. Urology, Mar. 1993 149(3) 519-22, abstract.
Stone et al., “Isolation of a Human Prostate Carcinoma Cell Line (DU 145)”,Int. J. Cancer, vol. 21, No. 3, Mar. 15, 1978, pp. 274-281.
Kaighn, et al., “Establishment and Characterization of a Human Prostatic Carcinoma Cell Line (PC-3)”,Investigative Urology, vol. 17, No. 1, Jul., 1979, pp. 16-23.
Johnson et al., “Localization of Mitochondria in Living Cells with Rhodamine 123”,Cell Biology, Proc. Natl. Acad. Sci. USA, Feb. 1980, pp. 990-994.
Peehl et al., “Clonal Growth of Human Keratinocytes with Small Amounts of Dialyzed Serum”, In Vitro, vol. 16, No. 6, Jun. 1980, pp. 526-540.
Lampidis et al., “Selective Toxicity of Rhodamine 123 in Carcinoma Cells In Vitro”,Cancer Research, vol. 43, Feb. 1983, pp. 716-720.
Bernal et al., “Rhodamine-123 Selectively Reduces Clonal Growth of Carcinoma Cells in Vitro”,Science, vol. 218, Dec. 10, 1982, pp. 1117-1119.
Horoszewicz et al., “LNCaP Model of Human Prostatic Carcinoma”,Cancer Research, vol. 43, Apr. 1983, pp. 1809-1818.
Bernal et al., “Anticarcinoma Activity in vivo of Rhodamine 123, a Mitochrondrial-Specific Dye”,Science, vol. 222, Oct. 14, 1983, pp. 169-172.
Lampidis et al., “Selective Killing of Carcinoma Cells <<in vitro>> by Lipophilic-Cationic Compounds: a Cellular Basis”, Biomed. Pharmacother., vol. 39, 1985, pp. 220-226.
Pollard et al., “Autochthonous Prostate Adenocarcinomas in Lobuund-Wistar Rats: A Model System”,The Prostate, vol. 11, No. 3, 1987, pp. 219-227.
Alley et al., “Feasibility of Drug Screening with Panels of Human Tumor Cell Lines Using a Microculture Tetrazolium Assay”,Cancer Research, vol. 48, Feb. 1, 1988, pp. 589-601.
Herr et al., “Anticarcinoma Activity of Rhodamine 123 Against a Murine Renal Adenocarcinoma”,Cancer Research, vol. 48, Apr. 15, 1988, pp. 2061-2063.
Goffney et al., “In Vitro and in Vivo Cytotoxicity of Rhodamine 123 Combined with Hyperthermia”,Cancer Research, vol. 50, Feb. 1, 1990, pp. 459-463.
Stamey et al., “Adenocarcinoma of the Prostate”,Campbell's Urology, Sixth Edition, Philadelphia, W.B. Saunders Co., 1992, pp. 1159-1221.
Sun et al., “AA1, a Newly Synthesized Monovalent Lipophilic Cation, Espresses Potent in Vivio Antitumor Activity”,Cancer Research, vol. 54, Mar. 15, 1994, pp. 1465-1471.
Ara, et al., “cis-Diamminedichloroplatinum(II) Resistant Human Tumor Cell Lines are Collaterally Sensitive to PtCl4(Rh-123)2: Evidence for Mitochondrial Involvement”,Cancer Research, vol. 54, Mar. 15, 1994, pp. 1497-1502.
Taplin et al., “Mutation of the Androgen-Receptor Gene in Metastatic Androgen-Independent Prostate Cancer”,The New England Jour. of Medicine, vol. 332, No. 21, May 25, 1995, pp. 1393-1398.
“Set 23: Potential-Sensitive Probes”, excerpt from Molecular Probes, Inc. literature (undated).
Fierz-David et al., Information About Mono-Äthyl-O-Toluidins and Some Rhodamines Obtainable Therefrom,Helv, Chem., Heta, 1934, pp. 1452-1459, with English translation.
Weiss et al.,Kodak Laboratory Chems. Bulletin, vol. 55, No. 2, 1984.
Banes et al., “High-Performance Liquid Chromatographic Quantitation of Rhodamines 123 and 110 From Tissues and Cultured Cells”,J. of Chromatrography, 356, 1986, pp. 301-309.
Arcadi, “Rhodamine-123 as Effective Agent in Rat Prostate Tumor R3327-H”,Urology, vol. XXVII, No. 6, Dec. 1986.
Castro et al., “Rhodamine-123 as a New Laser Dye: In Vivo Study of Dye Effects on Murine Metabolism, Histology and Ultrastructure”,Laryngoscope 99, Oct. 1989, pp. 1057-1062.
Arcadi, “Use of Rhodamine 123 in the Treatment of the Pollard III Rat Prostate Adenocarcinoma”,J. of Surg. Oncology, 1990, pp. 103-108.
Castro et al., “Photodynamic Therapy Using Rhodamine-123 as a New Laser Dye: Biodistribution, Metabolism and Histology in New Zealand Rabbits”,Laryngoscope 101, Feb. 1991, pp. 158-164.
Arcadi et al., “Studies of Rhodamine-123: Effect on Rat Prostate Cancer and Human Prostate Cancer Cells in Vitro”,J. of Surg. Oncology, 1995, pp. 86-93.
Wong et al., “Removal of Carcinoma Cells from Contaminated Bone Marrow Using the Lipophilic Cation Rhodamine 123”,Clinical Cancer Research, vol. 1, Jun. 1995, pp. 621-630.
Cook Rebecca
Huntington Medical Research Institutes
LandOfFree
Composition and method for treating carcinoma does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Composition and method for treating carcinoma, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Composition and method for treating carcinoma will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3547287